On June 25, Definium Therapeutics rose 9.07% in regular trading, trading at $45.455/share, with turnover of approximately $98.63 million. The stock continued its momentum driven by multiple positive catalysts over recent days.

On June 22, the company announced that its lead candidate DT120 oral disintegrating tablet achieved the primary endpoint and all key secondary efficacy endpoints in the pivotal Phase 3 EMERGE study for Major Depressive Disorder, demonstrating statistically significant and clinically meaningful improvement versus placebo, with a safety profile consistent with prior studies. Following this, RBC Capital raised its price target from $36 to $57, maintaining an Outperform rating.

Additionally, on June 24, the company completed the pricing of an upsized underwritten public offering of approximately 20.6 million shares at $34 per share, raising gross proceeds of approximately $700 million, up from the initially announced $500 million. Proceeds will fund research and development and general corporate purposes. The successful capital raise, combined with the landmark clinical data, reinforced investor confidence in the companys pipeline progression toward a potential regulatory submission.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)